Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment

EMS

Status and phase: Enrolling; Phase 3

Conditions: Hypertriglyceridemia; Dyslipidemia

Treatments: Drug: Crestor 10 mg; Drug: Cipros 10 association

Study type: Interventional

Funder types: Industry

Identifiers

NCT03527069

EMS0617-CIPROS

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy of Cipros 10 association in the treatment of Dyslipidemia Treatment

Enrollment: 298 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants of both sexes, aged 18 years or more;
• Participants with the diagnosis of Dyslipidemia presentinf low or intermediate cardiovascular risk, according to the Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;
• Signed consent.

Exclusion criteria

• Diagnosis of familial hypercholesterolemia and other genetic diseases;
• Using medications that may interfere with the metabolism or serum levels of triglycerides;
• Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
• Presence of concomitant cardiovascular disease, renal failure and hepatic Failure;
• Decompensated diabetes;
• Current smoking;
• History hypersensitivity to the active ingredients used in the study;
• Pregnancy or risk of pregnancy and lactating patients;
• History of alcohol abuse or illicit drug use;
• Participation in clinical trial in the year prior to this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

298 participants in 2 patient groups

CIPROS 10

Experimental group

Description:

The study is double-Masked, the patient wil take 2 tablets, as follow: 1 tablet Cipros 10 association; and 1 tablet crestor placebo Oral, once a day.

Treatment:

Drug: Cipros 10 association

Crestor

Active Comparator group

Description:

The study is double-Masked, the patient wil take 2 tablets, as follow: 1 tablet Crestor 10mg; and 1 tablet Cipros association placebo Oral, once a day.

Treatment:

Drug: Crestor 10 mg